新辅助化疗后ctDNA与CTC检测与三阴性乳腺癌复发相关:BRE12-158随机临床试验预设二次分析
该预设二次分析纳入BRE12-158试验中196例新辅助化疗后残留病灶的早期三阴性乳腺癌患者,检测治疗后ctDNA和CTC。ctDNA阳性与更差的无远处复发生存、无病生存和总生存独立相关;ctDNA与CTC双阳性患者预后最差,提示二者可作为术后风险分层指标。
要点
- 新辅助化疗后ctDNA阳性与更差DDFS、DFS和OS独立相关。
- ctDNA与CTC双阳性患者DDFS风险最高,24个月DDFS概率52%。
- ctDNA和CTC检测或可作为术后风险分层及后续试验分层因素。
核心结论
- 早期三阴性乳腺癌患者新辅助化疗后检测到ctDNA和CTC与疾病复发独立相关,是未来术后试验的重要分层因素。
研究设计与样本
- BRE12-158随机临床试验的预设二次分析,纳入196例新辅助化疗后残留病灶的早期三阴性乳腺癌女性患者。
- ctDNA与生存分析纳入142例,CTC与生存分析纳入123例,中位临床随访17.2个月(范围0.3-58.3个月)。
- ctDNA采用FoundationACT或FoundationOneLiquid Assay测序,CTC采用基于上皮细胞黏附分子的阳性选择微流控装置计数。
临床怎么用
- 对新辅助化疗后残留病灶的早期三阴性乳腺癌患者,可考虑检测ctDNA和CTC以辅助评估复发风险。
- ctDNA与CTC双阳性提示极高复发风险,可能需加强随访或纳入术后强化治疗临床试验。
局限性
- 为预设二次分析,ctDNA和CTC可评估样本量分别少于总纳入人群(142例和123例)。
- 中位随访17.2个月较短,长期预后关联需更长时间随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor cells (CTCs), may be used to detect minimal residual disease and assess which patients may experience disease recurrence. OBJECTIVE: To determine whether the presence of ctDNA and CTCs after neoadjuvant chemotherapy in patients with early-stage TNBC is independently associated with recurrence and clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: A preplanned secondary analysis was conducted from March 26, 2014, to December 18, 2018, using data from 196 female patients in BRE12-158, a phase 2 multicenter randomized clinical trial that randomized patients with early-stage TNBC who had residual disease after neoadjuvant chemotherapy to receive postneoadjuvant genomically directed therapy vs treatment of physician choice. Patients had blood samples collected for ctDNA and CTCs at time of treatment assignment; ctDNA analysis with survival was performed for 142 patients, and CTC analysis with survival was performed for 123 patients. Median clinical follow-up was 17.2 months (range, 0.3-58.3 months). INTERVENTIONS: Circulating tumor DNA was sequenced using the FoundationACT or FoundationOneLiquid Assay, and CTCs were enumerated using an epithelial cell adhesion molecule-based, positive-selection microfluidic device. MAIN OUTCOMES AND MEASURES: Primary outcomes were distant disease-free survival (DDFS), disease-free survival (DFS), and overall survival (OS). RESULTS: Among 196 female patients (mean [SD] age, 49.6 [11.1] years), detection of ctDNA was significantly associated with inferior DDFS (median DDFS, 32.5 months vs not reached; hazard ratio [HR], 2.99; 95% CI, 1.38-6.48; P = .006). At 24 months, DDFS probability was 56% for ctDNA-positive patients compared with 81% for ctDNA-negative patients. Detection of ctDNA was similarly associated with inferior DFS (HR, 2.67; 95% CI, 1.28-5.57; P = .009) and inferior OS (HR, 4.16; 95% CI,1.66-10.42; P = .002). The combination of ctDNA and CTCs provided additional information for increased sensitivity and discriminatory capacity. Patients who were ctDNA positive and CTC positive had significantly inferior DDFS compared with those who were ctDNA negative and CTC negative (median DDFS, 32.5 months vs not reached; HR, 5.29; 95% CI, 1.50-18.62; P = .009). At 24 months, DDFS probability was 52% for patients who were ctDNA positive and CTC positive compared with 89% for those who were ctDNA negative and CTC negative. Similar trends were observed for DFS (HR, 3.15; 95% CI, 1.07-9.27; P = .04) and OS (HR, 8.60; 95% CI, 1.78-41.47; P = .007). CONCLUSIONS AND RELEVANCE: In this preplanned secondary analysis of a randomized clinical trial, detection of ctDNA and CTCs in patients with early-stage TNBC after neoadjuvant chemotherapy was independently associated with disease recurrence, which represents an important stratification factor for future postneoadjuvant trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02101385.
引用
- Radovich M, Jiang G, Hancock BA, et al. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32644110. doi:10.1001/jamaoncol.2020.2295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。